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ABSTRACT
Objective: To assess the incremental cost and cost-
effectiveness of continuous and discontinuous
regimens of bevacizumab (Avastin) and ranibizumab
(Lucentis) for neovascular age-related macular
degeneration (nAMD) from a UK National Health
Service (NHS) perspective.
Design: A within-trial cost-utility analysis with a 2-year
time horizon, based on a multicentre factorial, non-
inferiority randomised controlled trial.
Setting: 23 hospital ophthalmology clinics.
Participants: 610 patients aged ≥50 years with
untreated nAMD in the study eye.
Interventions: 0.5 mg ranibizumab or 1.25 mg
bevacizumab given continuously (monthly) or
discontinuously (as-needed) for 2 years.
Main outcome measures: Quality-adjusted life-years
(QALYs).
Results: Total 2-year costs ranged from £3002/patient
($4700; 95% CI £2601 to £3403) for discontinuous
bevacizumab to £18 590/patient ($29 106; 95% CI
£18 258 to £18 922) for continuous ranibizumab.
Ranibizumab was significantly more costly than
bevacizumab for both continuous (+£14 989/patient
($23 468); 95% CI £14 522 to £15 456; p<0.001) and
discontinuous treatment (+£8498 ($13 305); 95% CI
£7700 to £9295; p<0.001), with negligible difference in
QALYs. Continuous ranibizumab would only be cost-
effective compared with continuous bevacizumab if the
NHS were willing to pay £3.5 million ($5.5 million) per
additional QALY gained. Patients receiving continuous
bevacizumab accrued higher total costs (+£599 ($938);
95% CI £91 to £1107; p=0.021) than those receiving
discontinuous bevacizumab, but also accrued non-
significantly more QALYs (+0.020; 95% CI −0.032 to
0.071; p=0.452). Continuous bevacizumab therefore
cost £30 220 ($47 316) per QALY gained versus
discontinuous bevacizumab. However, bootstrapping
demonstrated that if the NHS is willing to pay £20 000/
QALY gained, there is a 37% chance that continuous
bevacizumab is cost-effective versus discontinuous
bevacizumab.
Conclusions: Ranibizumab is not cost-effective
compared with bevacizumab, being substantially more
costly and producing little or no QALY gain.
Discontinuous bevacizumab is likely to be the most
cost-effective of the four treatment strategies evaluated
in this UK trial, although there is a 37% chance that
continuous bevacizumab is cost-effective.
Trial registration number: ISRCTN92166560.
INTRODUCTION
Neovascular age-related macular degener-
ation (nAMD) is a common disorder of the
ageing eye, which if left untreated leads to
severe central visual impairment. The
Strengths and limitations of this study
▪ We conducted a trial-based economic evaluation
based on high-quality data on costs and quality
of life prospectively collected within a rando-
mised trial.
▪ This demonstrated that bevacizumab would
achieve substantial cost-savings over ranibizu-
mab with negligible differences in quality of life.
In England, switching patients to bevacizumab
could save at least £102 ($160) million per year.
However, bevacizumab is not currently licensed
for neovascular age-related macular degeneration
(nAMD).
▪ Our study is the first trial-based economic evalu-
ation to evaluate the cost-effectiveness of alter-
native vascular endothelial growth factor inhibitor
treatments for nAMD.
▪ Of the strategies for the treatment of nAMD eval-
uated in this trial, we found discontinuous
(as-needed) bevacizumab to be the least costly
and most cost-effective. However, there was sub-
stantial uncertainty around this finding and sen-
sitivity analyses suggested that the
cost-effectiveness of using continuous (monthly)
treatment rather than discontinuous treatment
may vary between centres.
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current standard of care is treatment with biologicals
that bind to or inhibit vascular endothelial growth factor
(VEGF). Biologicals need to be injected into the vitreous
cavity of the eye at 4–8-week intervals. However, the ﬁrst
treatment convincingly shown to be effective in prevent-
ing vision loss (ranibizumab, Lucentis1 2) is expensive
(£742/dose in the UK3). Another anti-VEGF biological,
bevacizumab (Avastin), is licensed to treat cancer and
has been used to treat nAMD, using smaller doses that
cost much less than ranibizumab. Small non-randomised
studies on bevacizumab have reported outcomes that
were as good as those achievable with ranibizumab.4
Comparative effectiveness randomised controlled trials
(RCTs) of ranibizumab versus bevacizumab were there-
fore needed to provide unbiased estimates of relative
efﬁcacy and safety. The UK Inhibition of VEGF in
Age-related choroidal Neovascularisation (IVAN) trial5 6
and the US Comparison of Age-related macular degen-
eration Treatments Trials (CATT)7 8 were among the
ﬁrst such trials to report ﬁndings.
Two-year IVAN results demonstrated that ranibizumab
and bevacizumab produced similar improvements in
visual function, with no signiﬁcant difference in arterio-
thrombotic events or hospital admissions for heart
failure, which have previously been linked with
anti-VEGF therapy.5 IVAN also compared discontinuous
(as-needed) treatment against continuous monthly injec-
tions. Continuous and discontinuous treatment pro-
duced similar improvements in visual function, although
mortality was signiﬁcantly lower with continuous treat-
ment (p=0.05).
Given the rising demands for healthcare and limited
budgets, it is important to assess cost-effectiveness as well
as the clinical effectiveness and safety of medical inter-
ventions. Evidence on incremental cost and cost-
effectiveness is of particular importance in nAMD,
owing to the potential savings and health implications of
either reducing treatment frequency or substituting a
much cheaper alternative (bevacizumab) for a more
expensive drug (ranibizumab). Although ranibizumab
costs many times more than bevacizumab, it is important
to consider all relevant costs and assess cost-effectiveness
to determine whether the more expensive therapy has
added health beneﬁts that justify the additional costs or
lead to savings that offset the price difference.
A recent systematic review9 identiﬁed nine economic
evaluations of ranibizumab and three of bevacizumab.
Seven further studies evaluating ranibizumab10–16 and
two studies evaluating bevacizumab11 16 have since been
published. Most studies found ranibizumab to be cost-
effective versus other treatments, such as pegaptanib.
Five studies concluded that bevacizumab was likely to be
cost-effective compared with ranibizumab, of which four
studies relied on observational data11 15 or assumptions
about relative efﬁcacy.17 18 We are unaware of any other
RCT-based economic evaluation that has estimated the
cost-effectiveness of anti-VEGF treatment for nAMD.
A key objective of the IVAN trial was to assess the
incremental cost and incremental cost-effectiveness of
continuous and discontinuous regimens of bevacizumab
and ranibizumab in nAMD from the perspective of the
UK National Health Service (NHS). The results of these
analyses are reported here.
METHODS
The study was based on the 2-year results from the IVAN
trial (ISRCTN92166560), which provided high-quality
data on resource use and outcomes and comprises the
only UK trial directly comparing these interventions.
Trial design and methods have been described previ-
ously5 6; in brief, this was a factorial, multicentre non-
inferiority trial in which 610 patients not previously
treated for nAMD in their study eyes were randomised to
either bevacizumab (1.25 mg/dose) or ranibizumab
(0.5 mg/dose) and to either discontinuous treatment or
continuous monthly injections for 2 years. Discontinuous
treatment comprised an initial course of three monthly
injections, followed by further courses of three injections
given monthly if prespeciﬁed clinical and optical coher-
ence tomography (OCT) retreatment criteria were met.
The economic evaluation took a 2-year time horizon to
estimate within-trial cost-effectiveness as incremental
costs and quality-adjusted life-years (QALYs) appeared to
be relatively stable over time. Following UK guidelines,19
we took the perspective of the UK NHS, which excludes
costs incurred by patients and their families or employ-
ers. Detailed methods and additional results will be pub-
lished as a monograph in Health Technology Assessment.
As IVAN was factorial, it was important to consider the
likelihood of interactions, that is, whether the differ-
ences in costs and/or quality of life between bevacizu-
mab and ranibizumab differ between treatment
regimens. Although no interactions were anticipated for
visual acuity,6 large interactions between drug and treat-
ment regimen were expected for costs and cost-
effectiveness, as reducing the number of injections
would have a proportionately greater effect on drug
costs for ranibizumab than for less expensive bevacizu-
mab. Interactions for quality of life or costs were also
possible if the number of injections required for discon-
tinuous treatment differed between drugs. We therefore
estimated the mean costs and mean QALYs for each of
the four treatment combinations and interpreted the
results based on four pairwise comparisons:
▸ Continuous ranibizumab versus discontinuous
ranibizumab,
▸ Continuous bevacizumab versus discontinuous
bevacizumab,
▸ Continuous ranibizumab versus continuous
bevacizumab,
▸ Discontinuous ranibizumab versus discontinuous
bevacizumab.
We report two forms of economic evaluation.
Comparisons between drugs were based on cost-minimisation
2 Dakin HA, et al. BMJ Open 2014;4:e005094. doi:10.1136/bmjopen-2014-005094
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analysis, which compares costs between treatments that
are assumed to have identical health effects.20
Cost-minimisation analysis is appropriate only if the dif-
ference in cost is so large that no plausible difference in
efﬁcacy could cause the more costly treatment to be cost-
effective.21 22 This approach is justiﬁed for the compari-
sons between drugs because the large difference in drug
costs was inevitably going to be the main inﬂuence on
the incremental cost-effectiveness of ranibizumab versus
bevacizumab. We therefore prespeciﬁed that ranibizu-
mab and bevacizumab would be compared using cost-
minimisation analysis unless ranibizumab-treated patients
accrued ≥0.05 more EQ-5D QALYs than those receiving
bevacizumab. In contrast, we used cost-utility analysis, in
which health outcomes are measured in QALYs, to
compare continuous and discontinuous treatment, where
incremental costs are smaller.
Measurement and valuation of resource use
Our base case analysis also focused on resource use asso-
ciated with the study eye or associated with adverse
events (AEs) or serious adverse events (SAEs) that were
‘expected’, that is, previously linked to anti-VEGF treat-
ment (see online supplementary appendix).
Concomitant medications, hospitalisations and ambula-
tory consultations that were neither associated with the
study eye nor attributable to expected AEs or expected
SAEs were excluded to avoid including episodes of high
healthcare resource use unrelated to treatment (eg,
renal failure or cancer), which might otherwise have
swamped the main effect of treatment on costs.23
After enrolment, participants were monitored for
disease activity on a monthly basis with visual acuity
assessments, colour fundus imaging and OCT. Fundus
ﬂuorescein angiography (FFA) was undertaken at speci-
ﬁed visits and when OCT was insufﬁcient to reach a deci-
sion on disease activity. A prespeciﬁed algorithm was
used to determine the need for retreatment. Patients
allocated to discontinuous treatment began a new
course of three monthly injections whenever they met
retreatment criteria. However, costing analyses excluded
protocol-driven resource use; in particular, we assumed
that patients would not require colour fundus photog-
raphy, OCT or FFA unless this would affect treatment
decisions. As such, patients on discontinuous treatment
were assumed not to require these investigations at the
second or third visit in a course of three injections,
when treatment was mandated (ﬁgure 1). Similarly,
patients on continuous treatment were assumed to
require monitoring consultations only once every
3 months, on the grounds that ophthalmologists would
want information about disease progression periodically,
irrespective of whether treatment decisions are required.
Microcosting was used to estimate the cost of injection
and monitoring consultations as the available national
average costs24 25 are not nAMD-speciﬁc and do not dif-
ferentiate between consultations for monitoring and
intravitreal drug delivery. Staff at 13 of the 23 IVAN
centres completed questionnaires on overheads, the cost
of setting up clinic facilities and equipment and/or the
staff required to run injection and monitoring clinics.
The drug acquisition cost for ranibizumab was the
NHS list price (£742.173) and that for bevacizumab was
the price typically charged by the not-for-proﬁt NHS
provider used in the trial (£49/preﬁlled syringe). All
concomitant medications, contacts with medical profes-
sionals and hospitalisations were recorded at each
monthly clinic visit. Concomitant medications applied to
the study eye or indicated for any expected SAE/AE
were valued using list prices.3 Costs of other medica-
tions, including those applied to the fellow eye, were
excluded from the analysis. Unit costs for consultations
with general practitioners, district or general practice
nurses and hospital staff outside IVAN clinics were
obtained from routine sources.25 26 These costs were
applied to ambulatory consultations that were either
related to the eye or that occurred within 30 days of an
expected SAE/AE. Hospital stays linked to expected
Figure 1 Schematic illustrating the assumptions made about the frequency of injection and monitoring consultations within the
costing analysis. The consultations required by patients on discontinuous treatment will depend on when they met treatment
failure criteria; patient 2 met the retreatment criteria at visits 0, 7 and 11. ✓ Relevant consultation cost was applied. ? The cost of
fundus fluorescein angiography (FFA) was applied if clinically indicated: for discontinuous patients, this was applied whenever
the patient had FFA in the trial; for continuous patients, the proportion of patients having FFA was based on estimated use in
routine clinical practice. X No consultation cost was applied as the participant missed the visit.
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SAEs were valued using the mean cost per bed-day for
associated healthcare resource groups (HRGs).25
Resource use data and unit costs were combined to
estimate quarterly costs of bevacizumab/ranibizumab;
drug administration and monitoring consultations; and
hospitalisations, ambulatory consultations and medica-
tion changes for expected SAEs/AEs. Value added tax
(VAT) was excluded from the economic evaluation and
included in budget impact estimates, following guide-
lines.19 Costs are reported in 2011 pounds sterling,
accompanied by equivalents in US dollars (exchange
rate: $1.57/pound).
Measurement and valuation of health benefits
The three-level EQ-5D questionnaire27 was administered
at baseline, 3, 12 and 24 months, and (if the patient was
willing and able to do so) at study exit, after any SAE and
after a drop in visual acuity in the study eye of ≥15 letters
on the Early Treatment Diabetic Retinopathy Study
vision chart between two consecutive visits (referred to
subsequently as a ‘reduction in visual acuity’). The
Health Utilities Index questionnaire Mark 3 (HUI3) was
administered at the same timepoints and used in
sensitivity analysis; EQ-5D comprised the primary
utility measure following UK guidelines.19 Patients self-
completed large-print EQ-5D questionnaires, with
assistance from study nurses where necessary, responses
were valued using the UK time-trade-off tariff to give
‘utilities’.27
Missing utility data were imputed using multiple
imputation,28 which avoids bias and enables analysis of
the whole sample. Multiple imputation was conducted
using the ice command29 (V.1.9.4) in Stata V.12
(StataCorp, College Station, Texas, USA).
QALYs for each participant were calculated as the area
under the curve. We assumed that utility changed lin-
early between consecutive EQ-5D measurements in the
absence of SAEs. As linear changes are unlikely for
patients with SAEs, we assumed that SAEs and reduc-
tions in visual acuity caused a sudden drop in utility on
the day of onset, followed by a linear rise as the patient
recovered; the rate of this linear rise was estimated using
mixed models (see online supplementary appendix).
Statistical methods
Linear regression models were used to estimate the
effect of drug and treatment regimen on QALYs, drug
costs, administration/monitoring costs and medication/
medical service use in each 3-month period or ‘quarter’
(see online supplementary appendix). Interactions
between drug and treatment regimen were included in
the models for quarters 2–8 if they were either statistic-
ally signiﬁcant or were larger than the main effect for
drug or for treatment regimen. The analysis of QALYs,
drug costs and medication/medical service use in quar-
ters 2–8 therefore took account of interactions, while
drug and treatment regimen were assumed to have
additive effects on administration/monitoring costs.
A variant of Kaplan-Meier sample averaging30 31 was
used to account for patients withdrawing early from the
trial and excludes differences in mortality unrelated to
treatment; regression predictions of quarterly costs and
QALYs were weighted by the proportion of patients alive
at the start of each quarter. Costs and QALYs accrued in
year 2 were discounted at 3.5% to allow for time prefer-
ence (ie, the tendency to prefer beneﬁts sooner and
costs later).19 Uncertainty around quarterly costs and
QALYs was quantiﬁed by estimating models separately
for 130 non-parametric bootstrap draws on each of 100
data sets generated in multiple imputation to capture
the uncertainty around imputed utilities. The appendix
gives further details of the statistical methodology.
Presentation of results and uncertainty
Incremental cost-effectiveness ratios (ICERs) were calcu-
lated by dividing the difference in cost between two
study arms by the difference in QALYs. Results were
interpreted assuming that the UK NHS would be willing
to pay £20 000 to gain one QALY (a £20 000/QALY
‘ceiling ratio’).32 We also present net beneﬁts for each
of the four treatment arms: net beneﬁt equals total
QALYs multiplied by the ceiling ratio, minus total costs.
Uncertainty around ICERs is presented as cost-
effectiveness acceptability curves, which plot the prob-
ability of each of the four treatment regimens having
the highest net beneﬁts (ie, being most cost-effective) at
a range of ceiling ratios.
Sensitivity analyses evaluated the impact of changing
the costs (eg, halving the cost of ranibizumab), methods
(eg, taking a 1-year time horizon) and assumptions (eg,
including the costs of all SAEs, not just ‘expected’
SAEs).
RESULTS
QALYs and quality of life
The number of QALYs accrued over the 2-year trial
period did not differ signiﬁcantly between bevacizumab
and ranibizumab, or between continuous and discon-
tinuous treatments (p≥0.381; table 1). Patients rando-
mised to continuous treatment accrued non-signiﬁcantly
more QALYs than those randomised to discontinuous
treatment (mean difference: 0.020 (95% CI −0.032 to
0.071) for bevacizumab, p=0.452 and 0.026 (95% CI
−0.032 to 0.085) for ranibizumab, p=0.381), while differ-
ences between ranibizumab and bevacizumab were
negligible.
Resource use and costs
Patients receiving continuous treatment received a mean
of 22 injections, while those on discontinuous treatment
received 13 injections. Consequently, drug costs differed
substantially between continuous and discontinuous
treatments (table 1; p<0.001), as well as between ranibi-
zumab and bevacizumab (p<0.001). As reducing treat-
ment frequency produces larger savings for ranibizumab
4 Dakin HA, et al. BMJ Open 2014;4:e005094. doi:10.1136/bmjopen-2014-005094
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than for bevacizumab, there were signiﬁcant interactions
between drug and treatment regimen for drug cost
(p<0.001).
Administration of bevacizumab or ranibizumab costs
£61 ($96; SD: £14) per injection, while each consult-
ation for monitoring costs £72 ($113; SD: £41), plus £39
($61; SD: £16) for each FFA. Administering intravitreal
injections and monitoring disease progression/remission
cost between £1825 and £1970 per patient over the
2-year trial period (table 1). Discontinuous treatment
reduced the number of injections required, but
increased the number of monitoring consultations
needed to assess disease status against retreatment cri-
teria, as we assumed that OCT would only be performed
when it would inform treatment decisions. As continu-
ous treatment requires, on average, nine more injections
(p<0.001), but avoids only six monitoring visits
(p<0.001), drug administration and monitoring costs
were higher with continuous treatment than discontinu-
ous treatment (mean difference: £130 per patient
($204); 95% CI £20 to £239; p=0.021), with no signiﬁ-
cant difference between bevacizumab and ranibizumab
(p=0.80).
The cost of medication changes, hospitalisations and
ambulatory consultations associated with expected SAEs
and expected AEs was relatively small (mean: £469
($735) per patient), but varied substantially between
patients (95th centile range: £0, £1401). There was no
signiﬁcant difference in such costs between drugs or
between treatment regimens (p≥0.163).
Taking account of the drug cost, drug administration/
monitoring and medication/medical service use, the
mean total cost per patient over the 2-year trial ranged
from £18 590 ($29 119) for continuous ranibizumab to
£3002 ($4702) for discontinuous bevacizumab (table 1).
Drug cost accounted for 80–88% of the total cost for
patients randomised to ranibizumab and 21–30% of the
cost for patients randomised to bevacizumab. Drug
administration and monitoring accounted for 54–61%
of the costs accrued by patients randomised to bevacizu-
mab and 10–15% of the costs for those randomised to
ranibizumab.
Base case comparison between ranibizumab and
bevacizumab
As the difference in mean QALYs between ranibizumab
and bevacizumab was less than the prespeciﬁed non-
inferiority margin (0.05 QALYs), cost-minimisation ana-
lysis was used to compare the two drugs on the basis of
cost alone. Overall, continuous ranibizumab cost
£14 989 more per patient ($23 476 (95% CI £14 522 to
£15 456), table 1) than continuous bevacizumab over
the 2-year trial period (p<0.001). Discontinuous ranibi-
zumab costs £8498 more per patient ($13 308 (95% CI
£7700 to £9295), p<0.001) compared with discontinuous
bevacizumab. Bootstrapping analyses estimated the prob-
ability that switching from ranibizumab to bevacizumab
would save money and found that this exceeds 99.9%.
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Base case comparison between continuous and
discontinuous treatment
Overall, using continuous rather than discontinuous
treatment increased costs by £7090 ($11 102 (95% CI
£6337 to £7844), p<0.001) for ranibizumab and £599
($938 (95% CI £91 to £1107), p=0.021) for bevacizumab.
However, patients randomised to continuous bevacizu-
mab also accrued non-signiﬁcantly more QALYs than
those randomised to discontinuous bevacizumab (table 1;
p=0.452). In line with best practice,20 we took account of
the non-signiﬁcant differences in QALYs and allowed for
the joint distribution of costs and QALYs, as assuming
no difference in health outcomes can introduce bias
and give misleading conclusions.21 22 Dividing the differ-
ence in cost by the difference in QALYs suggests that
continuous bevacizumab costs £30 220 ($47 316) per
additional QALY gained compared with discontinuous
bevacizumab. This ICER is somewhat higher than the
£20 000 ($31 000) per QALY ‘ceiling ratio’ below which
the NHS generally considers treatments to be cost-
effective.32 However, the imprecision around QALY dif-
ferences means that there is substantial uncertainty
around this ICER. Bootstrapping demonstrated that
there is a 37% chance that continuous bevacizumab is
cost-effective compared with discontinuous bevacizumab
at a £20 000/QALY ceiling ratio, which increases to 50%
at £30 000/QALY.
Continuous ranibizumab costs £270 217 ($423 074)
per QALY gained compared with discontinuous ranibi-
zumab. Owing to the substantial savings possible by
giving ranibizumab less frequently, we can be >99.99%
conﬁdent that continuous ranibizumab is poor value for
money compared with discontinuous ranibizumab at a
£20 000/QALY ceiling ratio.
Base case four-way comparison
It is also informative to consider the four trial treatment
groups as four mutually exclusive alternative strategies
for managing nAMD. Framing the decision in this way
demonstrates that discontinuous bevacizumab is the
most cost-effective treatment strategy evaluated in IVAN,
generating higher net beneﬁts than the other three
treatment strategies (table 1), where net beneﬁt equals
QALYs multiplied by ceiling ratio (in this case £20 000/
QALY) minus costs. Continuous ranibizumab would only
be cost-effective compared with continuous bevacizumab
if the NHS were willing to pay £3.5 million ($5.5
million) per additional QALY gained. Discontinuous
ranibizumab is not cost-effective at any ceiling ratio, as it
is more costly and less effective than continuous or dis-
continuous bevacizumab.
However, there remains substantial uncertainty around
incremental QALY gains. This is illustrated by the cost-
effectiveness acceptability curves plotting the probability
of each treatment being the most cost-effective of the
four strategies at different ceiling ratios (ﬁgure 2). This
demonstrates that although we can be 98% conﬁdent
that discontinuous bevacizumab is less costly than
continuous bevacizumab, our conﬁdence in the conclu-
sion that discontinuous bevacizumab has the highest net
beneﬁts decreases rapidly as the value we place on the
small, non-signiﬁcant QALY gains increases. At a
£20 000/QALY ceiling ratio, there is a 63% probability
that discontinuous bevacizumab is the most cost-effective
strategy considered in IVAN and a 37% probability that
continuous bevacizumab is the most cost-effective. In
contrast, the probability of either continuous or discon-
tinuous ranibizumab being the most cost-effective strat-
egy for managing nAMD is <1% unless the NHS were
willing to pay more than £100 000/QALY gained.
Sensitivity analyses
Sensitivity analyses demonstrated that the conclusions
are very robust to changes in the assumptions and
methods used to measure costs and utilities and conduct
the analysis (ﬁgure 3). Of note, no sensitivity analysis
changed the conclusion that ranibizumab is not cost-
effective compared with bevacizumab, including analyses
discounting the ranibizumab list price by 50%. However,
three sensitivity analyses changed the conclusion that
continuous bevacizumab is not cost-effective compared
with discontinuous bevacizumab: assuming that FFA is
only conducted at baseline, not at any subsequent moni-
toring consultation; measuring quality of life using
HUI3 rather than EQ-5D; and using unadjusted
Kaplan–Meier estimates of the probability of surviving at
any point in time to account for censoring, rather than
excluding differences in deaths that were unrelated to
study medication (see online supplementary appendix).
Threshold analyses demonstrated that the price of
ranibizumab would need to be reduced to £63.46 per
Figure 2 Cost-effectiveness acceptability curve showing the
probability that each treatment is the most cost-effective
strategy evaluated in the UK Inhibition of VEGF in Age-related
choroidal Neovascularisation trial at a range of ceiling ratios.
For example, at a ceiling ratio of £20 000/quality-adjusted
life-year (QALY) gained (shown by the vertical dashed line),
there is a 63% probability that discontinuous bevacizumab is
best and a 37% probability that continuous bevacizumab is
best, while the probability that either ranibizumab treatment
regimen is best is approximately 0% (total=100%).
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dose (a 91% price reduction) in order for continuous
ranibizumab to be cost-effective compared with continu-
ous bevacizumab at a £20 000/QALY ceiling ratio.
DISCUSSION
This study demonstrates that in the setting of the UK
IVAN trial, we can be >99% conﬁdent that ranibizumab
represents very poor value for money compared with
bevacizumab at the £20 000 ($31 000) per QALY ceiling
ratio used within NHS decision-making.32 Continuous
ranibizumab would only be cost-effective compared with
continuous bevacizumab if the NHS were willing to pay
>£3.5 ($5.5) million/QALY gained. Furthermore, our
analysis also shows that giving discontinuous bevacizu-
mab, rather than discontinuous ranibizumab, could save
the UK NHS £8498 ($13 341) per patient treated, with
little or no impact on the health gains from treatment.
If the 17 295 eyes requiring anti-VEGF therapy each year
in England33 were switched from discontinuous ranibizu-
mab to discontinuous bevacizumab, the NHS could save
at least £102 ($160) million per year (including 20%
VAT) based on the treatment regimens evaluated in
IVAN. It remains controversial as to whether a drug (bev-
acizumab) that has not been approved and licensed for
nAMD by regulatory agencies should be used when a
licensed drug (ranibizumab) is available. In the UK, clin-
icians may prescribe unlicensed medications within
approved research projects, when no suitable medicine
is licensed, or when the licensed alternative is unavail-
able,34 although prescribing on cost grounds is not men-
tioned. By contrast, in the USA, ophthalmologists use
bevacizumab freely.35 National guidance (rather than
local hospital/clinician policies) is therefore needed in
the UK to direct the choice between bevacizumab and
ranibizumab. CATT and IVAN provide robust data to
guide regulators in this decision, demonstrating that
ranibizumab and bevacizumab have comparable effects
on vision and similar safety proﬁles,5 7 but that (based
on the current analysis of IVAN) ranibizumab costs £3.5
million per QALY compared with bevacizumab.
The base case analysis found that continuous bevacizu-
mab costs £30 220 ($47 445) per QALY gained com-
pared with discontinuous bevacizumab, suggesting that
Figure 3 Effect of sensitivity
analyses on total net benefits for
each of the four treatment arms,
assuming a £20 000/
quality-adjusted life-year (QALY)
ceiling ratio. Treatments that are
more cost-effective have higher
net benefits; the treatment
furthest to the right is therefore
most cost-effective, while the
treatment furthest to the left is the
least cost-effective. Error bars
represent 95% CIs. In the
analysis ‘doubling SAE impact’,
both the medication/medical
service use cost and the impact
of serious adverse events (SAEs)
on QALYs were doubled. The
‘best case’ analysis
simultaneously changed several
assumptions in favour of
ranibizumab: 50% discount off the
ranibizumab list price; assuming
that 15.9% of bevacizumab (as
occurred in the trial) but no
ranibizumab is wasted; assuming
that bevacizumab costs £100 per
dose; and including medical
service use costs associated with
expected and unexpected
adverse events (AEs) and SAEs.
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discontinuous bevacizumab is the most cost-effective
strategy evaluated in IVAN if the NHS is willing to pay
up to £20 000/QALY gained. However, there remains
substantial uncertainty around this conclusion and there
is a 37% chance that continuous bevacizumab is cost-
effective. The ﬁnding of non-signiﬁcantly higher QALYs
with continuous treatment contradicts our prior hypoth-
esis that avoiding monthly injections might improve
quality of life, although the observed difference could
be due to chance. Nevertheless, discontinuous bevacizu-
mab would remain the most cost-effective strategy even
if there were no difference in quality of life between
treatment regimens. Other considerations may affect the
choice of the anti-VEGF delivery model. In particular, as
discontinuous treatment requires regular clinical review
and access to retinal imaging, it may be more practical
to provide treatment every month, with monitoring
restricted to speciﬁed points in time (eg, 6 or 12 months
after initiation of therapy). Indeed, the label for the
newest anti-VEGF (aﬂibercept) incorporates a limited
clinical monitoring regime.36 The discontinuous treat-
ment regimen evaluated in the IVAN trial was chosen
partly to minimise the possibility of disadvantage to par-
ticipants in these groups and partly to minimise the
number of retreatment decisions required. Neither
monthly treatment nor treatments given as blocks of
three are used widely in routine practice, although fol-
lowing the publication of IVAN,5 6 there appears to be
increased interest in the ‘IVAN regimen’. The cost-
effectiveness of monthly treatment versus intermittent
treatment will therefore vary between treatment centres
depending on local costs and clinical practice.
Unlike previous studies, our analysis is based on high-
quality data from an RCT with prospective measure-
ments of costs and quality of life, which was powered to
exclude any clinically meaningful difference in visual
acuity. It therefore provides unequivocally unbiased esti-
mates of incremental costs and QALYs. Nevertheless,
our analysis conﬁrms the ﬁndings of previous economic
evaluations, namely that ranibizumab is not cost-effective
compared with bevacizumab.11 16 18 We are also (to the
best of our knowledge) the ﬁrst to evaluate the cost-
effectiveness of the discontinuous treatment regimen
used in IVAN. In addition to following best practice for
trial-based economic evaluation, this study includes
several novel aspects, such as measuring quality of life
after SAEs, excluding chance differences in deaths unre-
lated to treatment and allowing for the factorial design
by including only large or statistically signiﬁcant
interactions.
The study also estimates the cost of consultations to
administer ranibizumab/bevacizumab and monitor out-
comes, which could be used in other economic evalua-
tions. Microcosting shows the main drivers of
consultation costs and highlighted substantial variation
in costs between centres; this variation means that the
cost-effectiveness of continuous versus discontinuous
bevacizumab (but not ranibizumab vs bevacizumab) will
vary between centres. It is important to note that the
costs were calculated to assess incremental cost-
effectiveness in IVAN and should not be used to set the
prices at which hospitals are reimbursed. In particular,
they are bottom-up estimates that exclude unpaid over-
time and VAT and make assumptions about overheads
and proportion of staff-time spent on patient contacts.
In most settings, it is likely that the costs to healthcare
commissioners will be higher and subject to local nego-
tiations with care providers.
The base case analysis focused on mortality attributable
to study medication and the costs associated with
‘expected’ SAEs/AEs and excluded other costs. This
reduced the risk that chance differences in resource use
not associated with study medication could distort our
conclusions. However, it also meant that the unantici-
pated increase in the incidence of other SAEs (eg, gastro-
intestinal events) with bevacizumab5 6 (which comprised
the only difference in SAEs between drugs) was not taken
into account in the costing analysis. However, sensitivity
analyses including the cost of all SAEs/AEs gave the same
conclusions. Although hospitals receive a commercial-in-
conﬁdence discount off the list price of ranibizumab and
the price of bevacizumab varies between hospitals, the
conclusions were robust to substantial changes in drug
price. The study focused on the period of follow-up in
the trial and excluded costs and beneﬁts beyond year 2.
However, as incremental costs and QALYs remained rea-
sonably stable over time, this is unlikely to have affected
the conclusions. The analysis also uses data only from
IVAN, rather than synthesising all available evidence.
Further research is needed to assess the extent to
which the cost-effectiveness ﬁndings generalise to other
countries with different relative prices and management
of nAMD and SAEs/AEs. For example, the incidence of
SAEs was substantially lower in IVAN than CATT,5 7
although sensitivity analyses doubling the impact of
SAEs on costs and QALYs suggested that this did not
change the conclusions. The costs of the two drugs may
vary between centres within the UK as hospitals may use
different bevacizumab suppliers or have different dis-
counts on ranibizumab. Nevertheless, as we collected
very detailed information on resource use, policymakers
in other countries can review these data against their
own to examine their similarity and hence the applic-
ability of our ﬁndings to their setting. Future work com-
bining data from IVAN with that from other trials, such
as CATT,7 may help reduce uncertainty and evaluate the
extent to which the results can be generalised. However,
we believe that our primary ﬁnding of ranibizumab
representing very poor value for money compared with
bevacizumab does apply throughout the world.
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